News

Dantrolene could be a new therapeutic agent to improve neurological function and disease symptoms in neuropathic Gaucher disease (nGD), according to a collaborative research study developed on a mice model and led by Cincinnati Children’s Hospital Medical Center. The study, “Modulating ryanodine receptors with dantrolene attenuates neuronopathic phenotype in…

Researchers from Cincinnati Children’s Hospital Medical Center in Ohio described in detail the brain and behavioral abnormalities of a mouse model of chronic neuronopathic Gaucher disease. This information is invaluable and can be used for experimental designs to evaluate novel therapies for the disease in the future.

A new study identified a group of genes that may be involved in the development and severity of Gaucher disease. Researcher also found that memantine, a drug used in the treatment of Alzheimer’s disease, increased the life span of animal models with Gaucher disease (GD). The study, titled “Identification of…

A case of a woman with Gaucher disease who was also diagnosed with systemic lupus erythematosus has raised questions about whether the two conditions may be related. But researchers behind the study, titled “Gaucher disease and Lupus: A rare association?” published in the journal Nefrologia, admit that to…

Levels of a protein called progranulin (PGRN) are significantly lower in the blood of Gaucher disease (GD) patients compared to the general public according to a study conducted by a team of international researchers and led by Dr. Chuan-ju Liu of New York University School of Medicine.

Global Genes, a global advocacy nonprofit working for patients and families of rare and genetic diseases, will help hundreds of patient advocates worldwide, including those for Gaucher disease, with travel stipends up to $100,000 so that they can attend this year’s 5th Annual RARE Patient Advocacy Summit. The…

A recent review of substrate reduction therapy for Gaucher disease, by the National Health Institute Doutor Ricardo Jorge, in Portugal, explored how well the strategy performs and identifies areas of treatment improvement for Gaucher and other lysosomal storage disorders. Gaucher disease, caused by the lack of an enzyme called glucocerebrosidase, is typically managed with…

One of the most disabling aspects of Gaucher disease (GD) is skeletal issues that leave patients often experiencing bone pain and impaired mobility. In a recent case report, researchers described a young woman with GD reporting severe ankle pain, her physical examination results, and the treatment course that doctors applied. The report, titled “…

Patients with Gaucher disease (GD) exhibit higher levels of several markers of antioxidant defense compared to healthy controls, a finding that highlights the alterations associated with the disease and the mechanisms triggered to prevent further damage. The study of these alterations, “Oxidative stress parameters of Gaucher disease type I patients,”…

Cerdelga (eliglustat) was recently approved in the U.S. and Europe for the long-term treatment of a subset of adult patients with Gaucher disease type 1 (GD1). Researchers at Sanofi Genzyme analyzed results from several clinical trials with the goal of comparing Cerdelga with Cerezyme (imiglucerase), an enzyme replacement therapy drug. Results…